Año 2010 / Volumen 102 / Número 10
Original
NOD2, CD14 and TLR4 mutations do not influence response to adalimumab in patients with Crohn’s disease: a preliminary report

pp. 591-595

M. Barreiro-de Acosta, S. Ouburg, S. A. Morré, J. B. A. Crusius, A. Lorenzo, J. Potel, A. Salvador Peña and J. E. Domínguez-Muñoz

Resumen
Introduction: adalimumab is a recombinant fully-human monoclonal immunoglobulin (IgG1) antibody utilized in the treatment of Crohn´s disease. Unfortunately no clinical or genetic markers
exist to predict response to anti-tumor necrosis factor-alpha (TNF) therapy. The aim of this study was to evaluate the association between selected genes involved in cytokine regulation and response
to adalimumab treatment in Crohn’s disease.

Methods: twenty-four patients with Crohn’s disease either naïve (n = 8) or had lost response or were unable to tolerate the chimeric anti-TNF antibody infliximab (n=16) were enrolled in the
study. Patients were genotyped for main polymorphisms in NOD2, CD14 and TLR4 genes. Response to adalimumab treatment was defined as a decrease of Crohn’s disease activity index
of at least 100 points or a closure of at least 50% of fistulas in case of fistulizing Crohn’s disease.

Results: overall, 75% of patients did respond to treatment.
However, no statistically significant association was found between any of the genotypes and the response to adalimumab.

Conclusions: in our small study group no association between the studied polymorphisms and response to adalimumab was apparent. Systematic studies to search for genetic markers of response to anti-TNF therapy are necessary.
Share Button
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Artículos relacionados
Instrucciones para citar
M. Barreiro-de Acosta, S. Ouburg, S. A. Morré, J. B. A. Crusius, A. Lorenzo, J. Potel, A. Salvador Peña and J. E. Domínguez-Muñoz. NOD2, CD14 and TLR4 mutations do not influence response to adalimumab in patients with Crohn’s disease: a preliminary report. 591-595


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 234 veces.
Este artículo ha sido descargado 8 veces.
Compartir
Este artículo ha sido valorado por 1 lectores .
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2023 y Creative Commons. Revista Española de Enfermedades Digestivas